Clavanin A

General Information


DRACP ID  DRACP02065

Peptide Name   Clavanin A

Sequence  VFQFLGKIIHHVGNFVHGFSHVF

Sequence Length  23

UniProt ID  Not available

PubChem CID  Not available

Origin  Styela clava

Type  Native peptide

Classification

  

Active ACP Immune system stimulating peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
RAW 264.7 Mouse macrophage leukemia cell Leukemia LC50 >600 µM (35% cell death at 600 µM) MTT assay 48 h 1

Hemolytic Activity  Mouse erythrocytes: <10% Hemolysis=200 µM

Normal (non-cancerous) Cytotoxicity  Mouse fibroblasts L929: LC50>600 µM (35% cell death at 600 µM); HEK293: LC50>600 µM (40% cell death at 600 µM)

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02065

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Coordination bond: Val1<---Zn2+--->His17; Val1<---Zn2+--->His21

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C131H184N34O27

Absent amino acids  ACDEMPRTWY

Common amino acids  F

Mass  305971

Pl  9.71

Basic residues  5

Acidic residues  0

Hydrophobic residues  12

Net charge  5

Boman Index  887

Hydrophobicity  77.83

Aliphatic Index  101.3

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27804992

Title  An anti-infective synthetic peptide with dual antimicrobial and immunomodulatory activities

Doi 10.1038/srep35465

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPR_2002

DRACP is developed by Dr.Zheng's team.